Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma

<div>Chromosomal mapping and biological processes and mechanisms of DMDGs. (a) The location and distribution of DMDGs on chromosomes. (b) Expression of DMDGs and PCA analysis of methylation. (c) The ROC curve of classification performance of linear discriminant model based on the DMDG expression profile and methylation profile. (d) Results of KEGG pathway and GO enrichment in DMDGs, different colors represented different pathways, and wiring indicated a relationship between genes and pathways.</div>

Disease Markers

fig4

Figure 4

Figure 4: Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma 

Figure 4 | Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma 